Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs MasterCard Inc (MA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs MasterCard Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while MasterCard Inc trades at $604 (market cap $529.81B). The key difference: MasterCard Inc is far larger — about 59.7× Kymera Therapeutics Inc. Common Stock's market cap, and MasterCard Inc pays a 0.58% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and MasterCard Inc for 135 Days on average.
| KYMR | MA | |
|---|---|---|
Market Cap | $8.87B | $529.81B |
Volume | 779,107 | 3,710,695 |
Sector | Health | Financials |
52-Week High | $127.31 | $604.80 |
52-Week Low | $55.80 | $471.55 |
Typical Hold Time | 0 Days | 135 Days |
Enterprise Value | $8.26B | $542.84B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Mastercard (MA) trades at $603.24, up 1.37% on the day, with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with consistent revenue growth from $22.2B in 2022 to $32.8B in 2025, net income margins above 45%, and three consecutive quarterly earnings beats. Institutional buying activity remains strong, with multiple funds increasing positions in Q4 2025.
Outlook remains positive with 80% analyst buy ratings and $668.67 consensus price target, representing 11% upside. Key risks include payment industry disruption from stablecoins and AI-driven competitors, though Mastercard's aggressive innovation strategy and expanding digital inclusion initiatives provide growth catalysts. The stock trades near resistance at $603 with support at $591.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →
